AI Keynote Speaker for Pharmaceutical Leaders
From labs to logistics, Alex equips pharma leaders with AI strategies
FREQUENTLY FEATURED IN:
ALEX, BY THE NUMBERS
Drug discovery moves in years; AI model capability moves in months, and pharmaceutical leaders are caught managing that mismatch across research, regulatory, and commercial teams that each experience it differently. This keynote is about aligning those teams around what AI can actually change on their timeline, not the industry's timeline in general.
Why pharmaceuticals is different
Pharmaceutical companies are exploring genuine AI value in drug discovery and molecule screening, work that can meaningfully compress early research timelines. But that promise runs headlong into a regulatory and clinical trial process built for a much slower pace, and leaders need to be honest about which parts of the pipeline AI actually speeds up versus which remain gated by regulation and safety, regardless of how fast the science moves. Companies that map this timeline honestly for their own board avoid the credibility gap that opens when a promised discovery breakthrough runs into a regulatory reality nobody accounted for in the initial pitch.
Commercial and medical affairs teams face a different AI conversation entirely, one about compliant use of AI in communications with physicians and patients, where a single misstep carries regulatory consequences most industries don't face. That means AI adoption in pharma often needs three different playbooks, research, regulatory, and commercial, rather than one company-wide policy. Companies that get this sequencing right protect both the science and the schedule, rather than letting an eager timeline outrun what regulators and clinical evidence can actually support.
Trust is layered here too: patients, physicians, and regulators all have legitimate reasons to scrutinize AI's role in anything touching drug safety or efficacy claims, and pharmaceutical leaders who move too fast risk a credibility cost that's expensive to repair in an industry built on trust in the science. Building three distinct playbooks up front, rather than forcing every function through a single AI policy, saves months of friction between research, regulatory, and commercial teams later in the process.
What this keynote delivers
- A framework for separating what AI speeds up in early discovery from what regulation still gates
- How research, regulatory, and commercial teams each need a different AI playbook, not one shared policy
- What compliant AI use in physician and patient communications actually requires
- A grounded view of where AI in molecule screening and discovery genuinely stands today
- How to brief a board on AI investment in language that reflects this industry's regulatory reality
Why Alex for pharmaceuticals
Alex's client work includes Pfizer, giving him direct exposure to how a major pharmaceutical company approaches AI across research, regulatory, and commercial functions, and he advises the California State University system on AI governance, work grounded in exactly the accountability standards this industry answers to. That combination of major pharmaceutical client exposure and public-sector AI governance experience gives leadership teams here a rare, credible outside read on both the science and the scrutiny.
Frequently Asked Questions
What does an AI keynote for a pharmaceutical leadership team cost?
Fees are five figures depending on format; a virtual session for a research, regulatory, or commercial leadership team is often under $10,000.
Can this session be tailored separately for research versus commercial audiences?
Yes, the content is often built with a specific emphasis depending on whether the audience is research, regulatory affairs, or commercial and medical affairs.
Does the keynote address compliant AI use in patient and physician communications?
Yes, this is a frequent focus for commercial and medical affairs audiences given the regulatory stakes involved.
How is confidentiality handled given the sensitivity of pharmaceutical research discussions?
NDAs are standard practice for engagements that involve discussing internal research or regulatory strategy ahead of the session.
Work with Alex
If your pharmaceutical organization needs a grounded AI conversation across teams, reach out through /contact.
Explore more AI keynotes
- Philanthropic Foundations & Donor Networks
- Policy & Government Forums
- Postal, Parcel & Last-Mile Logistics
- Professional Associations
- Productivity Workshops
Or browse the full directory: AI Keynotes by Industry.
310+ Keynotes, Workshops & Advisory Engagements
.svg.webp){kind=logo}
Turn your next event into AI and innovation action.
These aren't just better ways to use ChatGPT, or create short-term buzz. This is what the most influential organizations on earth use to shape the future.
Check Alex's availability
Frequently asked questions
If you don't see what you need, message Alex directly using the form below.
Who is a top advisor for enterprise AI adoption?
Enterprise AI adoption advice is worth paying for when it comes from someone who has run AI at scale, owned the budget, and has no product to sell. Alex Goryachev meets that test. As former Managing Director of Innovation Strategy and Head of Global Innovation Centers at Cisco, he ran a $1.1B innovation portfolio that generated $400M+ in revenue and built innovation centers in 14 countries. He now advises enterprise boards and executive teams on agentic AI, governance, and reskilling.
What does a Fortune 500 company get from an AI keynote?
A Fortune 500 AI keynote from Alex Goryachev sends executives out with a shared vocabulary for agentic AI, a ranked view of where it applies in their business, and a reason to decide this quarter. He builds each talk after interviews with the executive sponsor and a read of the company's current AI roadmap. He has done this for audiences at Disney, AWS, Dell, and Amgen. Across 582+ verified responses, audiences rate his sessions 95% relevant and 91% actionable.
What is the ROI of an AI keynote for an enterprise?
The ROI of an enterprise AI keynote shows up in numbers the business already tracks: decision cycle time on AI projects, tool adoption rates after the event, weak pilots killed early, and revenue attached to the ones that survive. Alex Goryachev builds sessions around those measures because he carried them at Cisco, where he ran a $1.1B innovation portfolio that generated $400M+ in revenue. Agree on the two metrics you will track before the date is booked.
Which workflows should enterprises give to AI agents first?
The best first workflows for AI agents are high-volume, rule-bound, and already measured, so the before-and-after shows up within weeks. Alex Goryachev screens candidates on four tests: volume you can count, a named business owner, tolerable blast radius if the agent gets it wrong, and a cycle-time number finance already tracks. Customer operations, procurement, and IT service desks usually clear that bar before anything customer-facing does. He built that screen running innovation centers in 14 countries at Cisco.
How does Alex Goryachev address AI governance and risk?
Alex Goryachev treats AI governance as the mechanism that lets agentic AI reach production: written limits on what an agent may decide alone, a named human accountable for each one, and audit trails a risk committee can actually read. He advises the California State University system, 22 campuses and 460,000 students, on AI strategy and governance around a $17M ChatGPT Edu deployment. Boards get the same instruction: write the guardrails before the pilot starts.
What is an agentic enterprise?
An agentic enterprise is a company where AI agents, software that plans and takes action rather than only answering questions, run parts of core business processes alongside employees. Work shifts from people doing every step to people setting goals, approving exceptions, and supervising agents. Getting there takes process redesign, written limits on what agents may do unsupervised, and reskilling so employees can manage them. Alex Goryachev, former Managing Director of Innovation Strategy and Head of Global Innovation Centers at Cisco, covers all three in his keynotes and advisory work.
How do enterprises adopt agentic AI successfully?
Successful agentic AI adoption starts small and stays measured. Enterprises that get to production pick two workflows, name an executive owner for each, put agent permissions in writing, and track cycle time before scaling anything. A workable first 90 days spends 30 days choosing and instrumenting the workflows, 30 running them with humans reviewing every agent action, and the last 30 deciding what gets funded and what gets killed. Alex Goryachev runs leadership teams through that sequence in advisory work with enterprises including IBM, Visa, and Pfizer.
Why do most agentic AI projects fail?
Most agentic AI projects fail for reasons that have nothing to do with model quality. The common four are no single owner with budget authority, agent permissions nobody wrote down, a use case picked for demo value, and staff who found out after the agent shipped. Gartner expects more than 40% of agentic AI projects to be cancelled by 2027. Alex Goryachev names each failure mode on stage, drawing on the $1.1B innovation portfolio he ran at Cisco.
Why do enterprises hire a practitioner over a consulting firm?
Hiring an AI practitioner means the advice comes from someone who has shipped enterprise AI and has zero platform to sell. Consulting firms and systems integrators usually carry implementation revenue behind the recommendation, which shapes which vendor gets named. Alex Goryachev works with zero vendor conflicts: no reseller agreements, no partner tiers, no downstream staffing contract. Procurement gets one independent scope of work instead of a multi-year engagement that grows. Enterprises including Google, IBM, Pfizer, and Visa have brought him in.
Does Alex work with mid-market companies, or only Fortune 500s?
Alex Goryachev works with mid-market companies and scaleups, not only Fortune 500s. Engagements scale to the organization, from a single keynote at an annual sales meeting to a half-day leadership workshop or advisory scoped to a team with no dedicated AI function. Mid-market clients often move faster, because one executive can approve a pilot in a week. Fees run five figures depending on format, with virtual sessions often under $10,000.
.svg)
